翼状胬肉的发病机制及临床治疗进展
Pathogenesis and Advances in the Clinical Management of Pterygium
DOI: 10.12677/ACM.2023.13112555, PDF,   
作者: 贺梦欣, 余 萍*:青海大学附属医院眼科,青海 西宁
关键词: 翼状胬肉治疗角膜缘干细胞Pterygium Treatment Pathogenesis
摘要: 翼状胬肉是一种球结膜下纤维血管生长,穿过角膜缘并延伸到外周角膜,在某些情况下会导致严重的视觉并发症。据报道,该疾病在世界不同地区的患病率为1.2%至约40%。虽然翼状胬肉有各种危险因素,包括紫外线(UV)辐射、病毒感染、遗传因素、免疫因素、无菌性炎症和环境刺激,但翼状胬肉的发病机制主要与暴露于紫外线有关。手术是翼状胬肉的主要治疗方法,各种技术如裸巩膜、旋转结膜瓣、自体角膜缘结膜移植、羊膜移植和自体游离结膜移植用于翼状胬肉的切除。新的治疗方法似乎也大大减少了令人担忧的复发问题。
Abstract: Pterygium is a bulbar conjunctival fibrovascular growth that crosses the corneal limbus and ex-tends into the peripheral cornea, leading to serious visual complications in some cases. The preva-lence of the disease has been reported to range from 1.2% to approximately 40% in different parts of the world. Although there are various risk factors for pterygium, including ultraviolet (UV) radia-tion, viral infections, genetic factors, immunologic factors, aseptic inflammation, and environmental stimuli, the pathogenesis of pterygium is primarily related to exposure to UV light. Surgery is the mainstay of treatment for pterygium and various techniques such as bare sclera, rotational con-junctival flaps, autologous corneal limbal conjunctival grafts, amniotic membrane grafts and autol-ogous free conjunctival grafts are used for pterygium excision. Newer treatments also seem to have greatly reduced the worrisome problem of recurrence.
文章引用:贺梦欣, 余萍. 翼状胬肉的发病机制及临床治疗进展[J]. 临床医学进展, 2023, 13(11): 18209-18216. https://doi.org/10.12677/ACM.2023.13112555

参考文献

[1] Zaidi, S.B.H. and Ali Khan, W. (2021) Is Pterygium Morphology Related to Loss of Corneal Endothelial Cells? A Cross-Sectional Study. Clinical Ophthalmology, 15, 1259-1266. [Google Scholar] [CrossRef
[2] Zhao, D., Zhao, H., He, Y., et al. (2021) The Inhibitive Effects of Proteasome Inhibitor MG-132 on Pterygium Fibroblasts in vitro and the Potential Key Regulators Involved. Life Sciences, 270, Article ID: 119088. [Google Scholar] [CrossRef] [PubMed]
[3] Zhou, W.P., Zhu, Y.F., Zhang, B., et al. (2016) The Role of Ultravi-olet Radiation in the Pathogenesis of Pterygia (Review). Molecular Medicine Reports, 14, 3-15. [Google Scholar] [CrossRef] [PubMed]
[4] Shahraki, T., Arabi, A. and Feizi, S. (2021) Pterygium: An Update on Pathophysiology, Clinical Features, and Management. Therapeutic Advances in Ophthalmology, Vol. 13. [Google Scholar] [CrossRef] [PubMed]
[5] Wanzeler, A.C.V., Duarte, B., de Andrade, V.D.M., et al. (2018) Impact of Conjunctival Autograft on Pterygium Treatment: Evaluation of Related Symptoms and Patients’ Satisfaction after Surgery. Clinical Ophthalmology, 12, 833-837. [Google Scholar] [CrossRef
[6] Baheran, S.S., Alany, R.G., Schwikkard, S., et al. (2023) Pharmacological Treatment Strategies of Pterygium: Drugs, Biologics, and Novel Natural Products. Drug Discovery Today, 28, Article ID: 103416. [Google Scholar] [CrossRef] [PubMed]
[7] Martín-López, J., Pérez-Rico, C., Benito-Martínez, S., et al. (2021) The Role of the Stromal Extracellular Matrix in the Development of Pterygium Pathology: An Update. Journal of Clinical Medicine, 10, Article 5930. [Google Scholar] [CrossRef] [PubMed]
[8] Elgouhary, S.M., Elmazar, H.F., Naguib, M.I., et al. (2020) Role of Oxidative Stress and Vascular Endothelial Growth Factor Expression in Pterygium Pathogenesis and Prevention of Pter-ygium Recurrence after Surgical Excision. International Ophthalmology, 40, 2593-2606. [Google Scholar] [CrossRef] [PubMed]
[9] Zavala, J., Hernandez-Camarena, J.C., Salvador-Gálvez, B., et al. (2018) Extracellular Matrix and Fibroblast Injection Produces Pterygium-Like Lesion in Rabbits. Biological Research, 51, Article No. 15. [Google Scholar] [CrossRef] [PubMed]
[10] Tan, J., Vollmer-Conna, U., Tat, L., et al. (2019) Dry-Eye Disease in Recurrent Pterygium. Ophthalmic Research, 61, 199-203. [Google Scholar] [CrossRef] [PubMed]
[11] He, S. and Wu, Z. (2022) Biomarkers in the Occurrence and Development of Pterygium. Ophthalmic Research, 65, 481-492. [Google Scholar] [CrossRef] [PubMed]
[12] Watanabe, M., Tsugeno, Y., Sato, T., et al. (2023) TGF-β Isoforms Affect the Planar and Subepithelial Fibrogenesis of Human Conjunctival Fibroblasts in Different Manners. Biomedicines, 11, Article 2005. [Google Scholar] [CrossRef] [PubMed]
[13] Casciano, F., Zauli, E., Busin, M., et al. (2023) State of the Art of Pharmacological Activators of p53 in Ocular Malignancies. Cancers, 15, Article 3593. [Google Scholar] [CrossRef] [PubMed]
[14] Yazar, S., Cuellar-Partida, G., Mcknight, C.M., et al. (2015) Genetic and Environmental Factors in Conjunctival UV Autofluorescence. JAMA Ophthalmology, 133, 406-412. [Google Scholar] [CrossRef] [PubMed]
[15] Anguria, P., Carmichael, T., Ntuli, S., et al. (2013) Chronic Inflammatory Cells and Damaged Limbal Cells in Pterygium. African Health Sciences, 13, 725-730. [Google Scholar] [CrossRef] [PubMed]
[16] Romano, V., Steger, B., Kovacova, A., et al. (2016) Further Evidence for Heredity of Pterygium. Ophthalmic Genetics, 37, 434-436. [Google Scholar] [CrossRef] [PubMed]
[17] Sámano-Hernández, L., Garfias, Y., González-Márquez, H., et al. (2023) Human Papilloma Virus Presence and Its Physical Status in Primary Pterygium. Heliyon, 9, e16189. [Google Scholar] [CrossRef] [PubMed]
[18] Fernandes, M., Sangwan, V.S., Bansal, A.K., et al. (2005) Outcome of Pterygium Surgery: Analysis over 14 years. Eye, 19, 1182-1190. [Google Scholar] [CrossRef] [PubMed]
[19] Jee, D., Park, M., Lee, H.J., et al. (2015) Comparison of Treatment with Preservative-Free Versus Preserved Sodium Hyaluronate 0.1% and Fluorometholone 0.1% Eyedrops after Cataract Surgery in Patients with Preexisting Dry-Eye Syndrome. Journal of Cataract and Refractive Surgery, 41, 756-763. [Google Scholar] [CrossRef] [PubMed]
[20] Hwang, H.S., Cho, K.J., Rand, G., et al. (2018) Optimal Size of Pterygium Excision for Limbal Conjunctival Autograft Using Fibrin Glue in Primary Pterygia. BMC Ophthalmology, 18, Article No. 135. [Google Scholar] [CrossRef] [PubMed]
[21] Bilge, A.D. (2018) Comparison of Conjunctival Autograft and Conjunctival Transposition Flap Techniques in Primary Pterygium Surgery. Saudi Journal of Ophthalmology: Official Journal of the Saudi Ophthalmological Society, 32, 110-113. [Google Scholar] [CrossRef] [PubMed]
[22] Akbari, M. (2022) Update on Overview of Pterygium and Its Sur-gical Management. Journal of Population Therapeutics and Clinical Pharmacology, 29, e30-e45. [Google Scholar] [CrossRef] [PubMed]
[23] Sabater-Cruz, N., Dotti-Boada, M., Rios, J., et al. (2021) Postopera-tive Treatment Compliance Rate and Complications with Two Different Protocols after Pterygium Excision and Conjunc-tival Autografting. European Journal of Ophthalmology, 31, 932-937. [Google Scholar] [CrossRef] [PubMed]
[24] Paganelli, B., Sahyoun, M. and Gabison, E. (2023) Conjunctival and Limbal Conjunctival Autograft vs. Amniotic Membrane Graft in Primary Pterygium Surgery: A 30-Year Compre-hensive Review. Ophthalmology and Therapy, 12, 1501-1517. [Google Scholar] [CrossRef] [PubMed]
[25] Özdemi,r M. (2008) Conjunctival Z-Plasty for Pterygium: Com-parison with Conjunctival Autografting. Electronic Journal of General Medicine, 5, 84-89. [Google Scholar] [CrossRef
[26] Young, A.L. and Kam, K.W. (2019) Pterygium: Surgical Techniques and Choices. Asia-Pacific Journal of Ophthalmology, 8, 422-423. [Google Scholar] [CrossRef
[27] Kaufman, S.C., Jacobs, D.S., Lee, W.B., et al. (2013) Op-tions and Adjuvants in Surgery for Pterygium: A Report by the American Academy of Ophthalmology. Ophthalmology, 120, 201-208. [Google Scholar] [CrossRef] [PubMed]
[28] Luanratanakorn, P., Ratanapakorn, T., Suwan-Apichon, O., et al. (2006) Randomised Controlled Study of Conjunctival Autograft versus Amniotic Membrane Graft in Pterygium Excision. The British Journal of Ophthalmology, 90, 1476-1480. [Google Scholar] [CrossRef] [PubMed]
[29] Fakhry, M.A. (2011) The Use of Mitomycin C with Autologous Limbal-Conjunctival Autograft Transplantation for Management of Recurrent Pterygium. Clinical Ophthalmology, 5, 123-127. [Google Scholar] [CrossRef
[30] Mutlu, F.M., Sobaci, G., Tatar, T., et al. (1999) A Comparative Study of Recurrent Pterygium Surgery: Limbal Conjunctival Autograft Transplantation versus Mitomycin C with Conjunctival Flap. Ophthalmology, 106, 817-821. [Google Scholar] [CrossRef
[31] Zhang, Q., Bao, N., Liang, K., et al. (2018) Adjuvant Use of Cyclosporine A in the Treatment of Primary Pterygium: A Systematic Review and Meta-Analysis. Cornea, 37, 1000-1007. [Google Scholar] [CrossRef
[32] Mandal, A., Gote, V., Pal, D., et al. (2019) Oc-ular Pharmacokinetics of a Topical Ophthalmic Nanomicellar Solution of Cyclosporine (Cequa®) for Dry Eye Disease. Pharmaceutical Research, 36, Article No. 36. [Google Scholar] [CrossRef] [PubMed]
[33] Zhai, L.Y., Zhang, X.R., Liu, H., et al. (2020) Observation of Topical Tacrolimus on High-Risk Penetrating Keratoplasty Patients: A Randomized Clinical Trial Study. Eye, 34, 1600-1607. [Google Scholar] [CrossRef] [PubMed]
[34] Hacioğlu, D. and Erdöl, H. (2017) Developments and Current Approaches in the Treatment of Pterygium. International Ophthalmology, 37, 1073-1081. [Google Scholar] [CrossRef] [PubMed]
[35] Wu, H. and Chen, G. (1999) Cyclosporine A and Thiotepa in Prevention of Postoperative Recurrence of Pterygium. Yan Ke Xue Bao, 15, 91-92. (In Chinese)
[36] Yu, J., Feng, J., Jin, T., et al. (2021) The Effect of a Novel Strategy in Treating Primary Pterygium: A Prospective Randomized Clinical Study. American Journal of Ophthalmology, 225, 108-116. [Google Scholar] [CrossRef] [PubMed]
[37] Yin, M., Li, H., Zhang, Y., et al. (2019) Interferon Alpha-2b Eye Drops Prevent Recurrence of Pterygium after the Bare Sclera Technique: A Single-Center, Sequential, and Controlled Study. Cornea, 38, 1239-1244. [Google Scholar] [CrossRef
[38] Razeghinejad, M.R. and Banifatemi, M. (2014) Subconjunc-tival Bevacizumab for Primary Pterygium Excision; A Randomized Clinical Trial. Journal of Ophthalmic & Vision Re-search, 9, 22-30.
[39] Fallah, M.R., Khosravi, K., Hashemian, M.N., et al. (2010) Efficacy of Topical Bevacizumab for Inhibiting Growth of Impending Recurrent Pterygium. Current Eye Research, 35, 17-22. [Google Scholar] [CrossRef] [PubMed]
[40] Papathanassiou, M., Theodossiadis, P.G., Liarakos, V.S., et al. (2008) Inhibition of Corneal Neovascularization by Subconjunctival Bevacizumab in an Animal Model. American Jour-nal of Ophthalmology, 145, 424-431. [Google Scholar] [CrossRef] [PubMed]
[41] Mansour, A.M. (2009) Treatment of Inflamed Pterygia or Residual Pterygial Bed. The British Journal of Ophthalmology, 93, 864-865. [Google Scholar] [CrossRef] [PubMed]
[42] Kim, H.K., Choi, J.Y., Park, S.M., et al. (2017) Tyrosine Kinase In-hibitor, Vatalanib, Inhibits Proliferation and Migration of Human Pterygial Fibroblasts. Cornea, 36, 1116-1123. [Google Scholar] [CrossRef